Showing results (701-710 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|March 8, 2017
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialMax Schreuer, Yanina Jansen, Simon Planken, et al.
The Lancet. Oncology|March 9, 2017
iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Perrone, et al.
The Lancet. Oncology|May 9, 2014
Addressing overdiagnosis and overtreatment in cancer: a prescription for changeLaura J Esserman, Ian M Thompson, Brian Reid, et al.
The Lancet. Oncology|March 15, 2021
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Laura J van 't Veer, Coralie Poncet, et al.
The Lancet. Oncology|March 15, 2021
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 studyJohn Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 12, 2021
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trialSjoukje F Oosting, Astrid A M van der Veldt, Corine H GeurtsvanKessel, et al.
The Lancet. Oncology|November 15, 2021
Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort studyKelvin César de Andrade, Payal P Khincha, Jessica N Hatton, et al.
The Lancet. Oncology|October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trialKent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Pageof 336